Characterization, quantification and stability of differently prepared amorphous forms of some oral hypoglycaemic agents

Pharmaceutical Development and Technology

Volumn 18, Issue 2, 2013, Pages 504-514

  Chadha, Renu ^a   Bhandari, Swati ^a   Arora, Poonam ^a   Chhikara, Rekha ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Amorphous; Calorimetry; Enthalpy of solution; Gliclazide; Glipizide; Repaglinide

Indexed keywords

GLICLAZIDE; REPAGLINIDE;

ARTICLE; CALORIMETRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; ENTHALPY; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VAPORIZATION; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG STABILITY; HUMIDITY; HYPOGLYCEMIC AGENTS; PHARMACEUTICAL SOLUTIONS; PHASE TRANSITION; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; WATER; X-RAY DIFFRACTION;

EID: 84872470263     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.723719     Document Type: Article

References (25)

1. Hancock BC. Disordered drug delivery: Destiny, dynamics and the Deborah number. J Pharm Pharmacol 2002;54:737-746 (Pubitemid 34649460)
2. Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C et al. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur J Pharm Biopharm 2009;71:71-79
3. Stubberud L, Forbes RT. The use of gravimetry for the study of the effect of additives on the moisture induced recrystallization of amorphous lactose. Int J Pharm 1998;163:145-156 (Pubitemid 28162628)
4. Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 1994;83:1700-1705
5. Imaizumi H, Nambu N, Nagai T. Stability and several physical properties of amorphous and crystalline form of indomethacin. Chem Pharm Bull 1980;28:2565-2569 (Pubitemid 11208718)
6. Otsuka M, Kaneniwa N. A kinetic study of the crystallization process of noncrystalline indomethacin under isothermal conditions. Chem Pharm Bull 1988;36:4026-4032 (Pubitemid 18266846)
7. Graeser KA, Strachan CJ, Patterson JE, Gordon KC. Physicochemical properties and stability of two differently prepared amorphous forms of simvastatin. Cryst Growth Des 2008;8:128-135
8. Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res 2004;21:1167-1176 (Pubitemid 38960768)
9. Jojart-Laczkovich O, Szabo-Revesz P. Amorphization of a crystalline active pharmaceutical ingredient and thermo analytical measurements on this glassy form. J Therm Anal Calorim 2010;102:243-247
10. Otsuka M, Nishizawa J, Fukura N, Sasaki T. Characterization of Poly-amorphous Indomathacin by Tetra-Hertz spectroscopy. J Infrared Milli Tetrahz Waves 2012;33:953-962
11. Kawashima Y, Saito M, Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicylic acid by a spraydrying technique. J Pharm Pharmacol 1975;27:1-5
12. Florence AT, Salole EG, Stenlake JB. The effect of particle size reduction on digoxin crystal properties. J Pharm Pharmacol 1974;26:479-480
13. Pikal MJ, Lukes AL, Lang JE. Thermal decomposition of amorphous beta-lactam antibacterials. J Pharm Sci 1977;66:1312-1316 (Pubitemid 8163987)
14. Fagegaltier N, Lamure C, Caron A, Mifsud H, Bauer M. Thermal analysis of amorphous phase in a pharmaceutical drug. J Therm Anal Calorim 1997;48:459-464 (Pubitemid 127782085)
15. Offerdahl TJ, Salsbury JS, Dong Z, Grant DJ, Schroeder SA, Prakash I et al. Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy. J Pharm Sci 2005;94:2591-2605 (Pubitemid 43265384)
16. Chen X, Bates S, Morris KR. Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J Pharm Biomed Anal 2001;26:63-72 (Pubitemid 32635284)
17. Pikal MJ, Lukes AL, Lang JE, Gaines K. Quantitative crystallinity determinations for beta-lactam antibiotics by solution calorimetry: Correlations with stability. J Pharm Sci 1978;67:767-773 (Pubitemid 8355230)
18. Hancock C, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397-404 (Pubitemid 30395293)
19. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 2006;95:1641-1665 (Pubitemid 44229572)
20. Chadha R, Kashid N, Jain DVS. Characterization and quantification of amorphous content in some selected parenteral cephalosporins by calorimetric method. J Therm Ana Cal 2005;81:277-284 (Pubitemid 41164952)
21. Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 2001;48:27-42 (Pubitemid 32454482)
22. Kumar Y, Ray PC, Babu JS. Process for the preparation of amorphous form of repaglinide. WO/2005/021524, (2005
23. Shavi GP, Kumar AR, Yogendra NU, Armugam K, Ranjan OP, Ginjupalli K et al. Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques. Int J Drug Deliv 2010;2:49-57
24. Purvis T, Mattucci ME, Crisp MT, Johnston KP, Williams RO 3rd. Rapidly dissolving repaglinide powders produced by the ultrarapid freezing process. AAPS PharmSciTech 2007;8:E58
25. Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998;87:1615-1621 (Pubitemid 28559651)